Ongoing clinical trials and approved products targeting SSTR 2/3, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.
Theranostic pair: this target is explored in both imaging and therapy.
| Lutathera[177Lu]Lu-oxodotreotide (DOTATATE) | Novartis (AAA) | marketed | US EU FR JP |
| Bexlutry[177Lu]Lu-dotatate (Lutathera equivalent) | Curium | approved (launch pending) | US |
| DOTATATE / DOTATOC (Netspot, SomaKit TOC…)[68Ga]Ga-DOTA-TATE, [68Ga]Ga-edotreotide | Novartis (AAA), UIHC, génériques | marketed | US EU FR |
| Detectnet[64Cu]Cu-DOTATATE | Curium | marketed | US |
| Octreoscan[111In]In-pentetreotide | Curium | marketed | US EU FR JP |
| Tektrotyd[99mTc]Tc-HYNIC-TOC | Polatom | marketed (national authorisations) | EU FR |
| Trial | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
| COMPETE · [177Lu]Lu-edotreotide (ITM-11)NCT03049189 · Gastroenteropancreatic NETs | Phase 3 | Active, not recruiting | ITM Solucin GmbH | 14 |
| COMPOSE · [177Lu]Lu-edotreotide (ITM-11)NCT04919226 · Gastroenteropancreatic NETs | Phase 3 | Active, not recruiting | ITM Solucin GmbH | 10 |
| NETTER-3 · [177Lu]DOTATATENCT06784752 · Gastroenteropancreatic NETs | Phase 3 | Recruiting | Novartis Pharmaceuticals | 12 |
| ACTION-1 · RYZ101 ([225Ac]Ac-DOTATATE)NCT05477576 · Gastroenteropancreatic NETs | Phase 3 | Active, not recruiting | RayzeBio, Inc. | 8 |
| NETTER-2 · [177Lu]DOTATATENCT03972488 · Gastroenteropancreatic NETs | Phase 3 | Active, not recruiting | Advanced Accelerator Applications | 9 |
| [177Lu]DOTATATENCT05459844 · Gastroenteropancreatic NETs | Phase 3 | Active, not recruiting | Sinotau Pharmaceutical Group | 1 |
| [177Lu]DOTATATENCT05884255 · Gastroenteropancreatic NETs | Phase 3 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 1 |
| [177Lu]DOTATATENCT07057622 · NETs and neuroendocrine carcinomas (other) | Phase 3 | Recruiting | HTA Co., Ltd. | 1 |
| START-NET · [177Lu]Lu-edotreotide (ITM-11)NCT05387603 · NETs and neuroendocrine carcinomas (other) | Phase 3 | Recruiting | Lund University Hospital | 1 |
| LEVEL · [177Lu]Lu-edotreotide (ITM-11)NCT05918302 · NETs and neuroendocrine carcinomas (other) | Phase 3 | Recruiting | Grupo Espanol de Tumores Neuroendocrinos | 4 |
| PReCedeNT · [177Lu]DOTATATENCT07185672 · Gastroenteropancreatic NETs | Phase 3 | Recruiting | Tata Memorial Hospital | 1 |
| [177Lu]DOTATATE2024-518236-36-00 · Gastroenteropancreatic NETs | Phase 3 | Recruiting | Philipps-Universitaet Marburg | 1 |
| RIALTO · [177Lu]DOTATATENCT06878664 · Gastroenteropancreatic NETs | Phase 3 | Recruiting | Grupo Espanol de Tumores Neuroendocrinos | 2 |
| [177Lu]DOTATATENCT06398444 · NETs and neuroendocrine carcinomas (other) | Phase 3 | Recruiting | Sinotau Pharmaceutical Group | 1 |
| [90Y]DOTATATE2024-516503-17-01 · NETs and neuroendocrine carcinomas (other) | Phase 3 | Not yet recruiting | Narodowe Centrum Badan Jadrowych | 1 |
| LUMEN-1 · [177Lu]DOTATATENCT06326190 · Meningioma | Phase 2 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 6 |
| [177Lu]DOTATATENCT05773274 · Gastroenteropancreatic NETs | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2 |
| [177Lu]DOTATATENCT04665739 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Recruiting | National Cancer Institute (NCI) | 1 |
| [177Lu]DOTATATENCT05142696 · Small-cell lung cancer | Phase 2 | Active, not recruiting | Novartis Pharmaceuticals | 12 |
| MOMENTUM-1 · [177Lu]DOTATATENCT06955169 · Meningioma | Phase 2 | Recruiting | RTOG Foundation, Inc. | 1 |
| [177Lu]DOTATATENCT05724108 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | 1 |
| DOBATOC · [177Lu]Lu-edotreotide (ITM-11)NCT04917484 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Recruiting | Tine Gregersen, MD | 1 |
| [177Lu]DOTATATENCT05247905 · Gastroenteropancreatic NETs | Phase 2 | Active, not recruiting | Alliance for Clinical Trials in Oncology | 1 |
| LUMOD-ID · [177Lu]DOTATATENCT06395402 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Recruiting | University of Iowa | 1 |
| ReLUTH · [177Lu]DOTATATENCT04954820 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Recruiting | Institut du Cancer de Montpellier - Val d'Aurelle | 1 |
| [212Pb]VMT-α-NETNCT05636618 · Pheochromocytoma / paraganglioma | Phase 2 | Recruiting | Perspective Therapeutics | 1 |
| [177Lu]DOTATATENCT03206060 · Pheochromocytoma / paraganglioma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 1 |
| ALPHAMEDIX02 · [212Pb]DOTAMTATE (AlphaMedix)NCT05153772 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Active, not recruiting | Orano Med LLC | 1 |
| P-PRRT · [177Lu]DOTATATENCT02754297 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Active, not recruiting | CHU de Quebec-Universite Laval | 1 |
| [177Lu]DOTATATENCT05691465 · Prostate – other | Phase 2 | Recruiting | National Cancer Institute (NCI) | 1 |
| [177Lu]DOTATATENCT04082520 · Meningioma | Phase 2 | Recruiting | Mayo Clinic | 1 |
| [177Lu]DOTATATENCT05278208 · Meningioma | Phase 2 | Recruiting | Nationwide Children's Hospital | 1 |
| [177Lu]DOTATATENCT03971461 · Meningioma | Phase 2 | Active, not recruiting | NYU Langone Health | 1 |
| LUFOR · [177Lu]Lu-edotreotide (ITM-11)NCT06045260 · Pheochromocytoma / paraganglioma | Phase 2 | Recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 1 |
| TRACY-1 · RYZ101 ([225Ac]Ac-DOTATATE)NCT06590857 · Breast | Phase 2 | Recruiting | RayzeBio, Inc. | 3 |
| NETTER-P · [177Lu]DOTATATENCT04711135 · Pheochromocytoma / paraganglioma | Phase 2 | Active, not recruiting | Advanced Accelerator Applications | 5 |
| PROMENADE · [177Lu]Lu-edotreotide (ITM-11)NCT04997317 · Meningioma | Phase 2 | Recruiting | University Hospital, Basel, Switzerland | 1 |
| [212Pb]DOTATATENCT06427798 · Pheochromocytoma / paraganglioma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 1 |
| [177Lu]DOTATATENCT02236910 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Active, not recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 |
| [177Lu]DOTATATENCT04086485 · Gastroenteropancreatic NETs | Phase 2 | Recruiting | National Cancer Institute (NCI) | 1 |
| GoTHAM · [177Lu]DOTATATENCT04261855 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Active, not recruiting | Melanoma and Skin Cancer Trials Limited | 1 |
| RYZ101 ([225Ac]Ac-DOTATATE)NCT07150806 · Meningioma | Phase 2 | Recruiting | Joshua Palmer | 1 |
| LuDO-N · [177Lu]DOTATATENCT04903899 · Neuroblastoma | Phase 2 | Recruiting | Jakob Stenman | 5 |
| iPRRT · [177Lu]DOTATATENCT05583708 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Recruiting | Weill Medical College of Cornell University | 1 |
| [177Lu]DOTATATENCT06121271 · Pheochromocytoma / paraganglioma | Phase 2 | Not yet recruiting | University College, London | 0 |
| TENET · [161Tb]DOTATATENCT07404176 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Recruiting | Tata Memorial Hospital | 1 |
| [177Lu]DOTATATENCT04529044 · Breast | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 1 |
| LUTARTERIAL · [177Lu]DOTATATENCT04837885 · Gastroenteropancreatic NETs | Phase 2 | Recruiting | University Hospital, Bordeaux | 1 |
| ELUMEN · [177Lu]DOTATATENCT06126588 · Meningioma | Phase 2 | Recruiting | Central Hospital, Nancy, France | 1 |
| LUPARPED · [177Lu]DOTATATENCT06607692 · Neuroblastoma | Phase 2 | Recruiting | Fundación de investigación HM | 1 |
| [177Lu]DOTATATENCT05109728 · Brain (glioma, medulloblastoma…) | Phase 1 | Active, not recruiting | Novartis Pharmaceuticals | 5 |
| RYZ401NCT07165132 · Gastroenteropancreatic NETs | Phase 1 | Recruiting | RayzeBio, Inc. | 2 |
| KinLET · [177Lu]Lu-edotreotide (ITM-11)NCT06441331 · NETs and neuroendocrine carcinomas (other) | Phase 1 | Recruiting | ITM Solucin GmbH | 3 |
| [212Pb]DOTATATENCT06479811 · Neuroblastoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 1 |
| [177Lu]DOTATATENCT04234568 · Gastroenteropancreatic NETs | Phase 1 | Active, not recruiting | National Cancer Institute (NCI) | 1 |
| [177Lu]DOTATATENCT05687123 · Gastroenteropancreatic NETs | Phase 1 | Recruiting | National Cancer Institute (NCI) | 2 |
| [177Lu]DOTATATENCT04750954 · Gastroenteropancreatic NETs | Phase 1 | Active, not recruiting | National Cancer Institute (NCI) | 1 |
| [177Lu]DOTATATENCT06663072 · Gastroenteropancreatic NETs | Phase 1 | Recruiting | University of Chicago | 1 |
| 177Lu-DOTA-SNA040NCT07595237 · Pancreas (adenocarcinoma) | Phase 1 | Recruiting | SmartNuclide Biopharma | 1 |
| [177Lu]DOTATATENCT04544098 · Gastroenteropancreatic NETs | Phase 1 | Active, not recruiting | Memorial Sloan Kettering Cancer Center | 1 |
| [225Ac]DOTATATENCT06732505 · NETs and neuroendocrine carcinomas (other) | Phase 1 | Recruiting | Peking University Cancer Hospital & Institute | 1 |
| PARLuNET · [177Lu]Lu-DOTATATE + talazoparibNCT05053854 · NETs and neuroendocrine carcinomas (other) | Phase 1 | Recruiting | Peter MacCallum Cancer Centre, Australia | 1 |
| LANTana · [177Lu]DOTATATENCT05178693 · NETs and neuroendocrine carcinomas (other) | Phase 1 | Recruiting | Imperial College London | 1 |
| PRRT-PARPi · [177Lu]Lu-DOTATATE + olaparibNCT05870423 · NETs and neuroendocrine carcinomas (other) | Phase 1 | Recruiting | Erasmus Medical Center | 1 |
| [212Pb]VMT-α-NETNCT06148636 · NETs and neuroendocrine carcinomas (other) | Phase 1 | Active, not recruiting | David Bushnell | 1 |
| [225Ac]DOTATATENCT07413042 · Small-cell lung cancer | Phase 1 | Recruiting | Peking University Cancer Hospital & Institute | 1 |
| [177Lu]Lu-edotreotide (ITM-11)NCT03044977 · Gastroenteropancreatic NETs | Phase 1 | Active, not recruiting | David Bushnell | 1 |
| [177Lu]DOTATATENCT07150546 · NETs and neuroendocrine carcinomas (other) | Phase 1 | Recruiting | Emory University | 1 |
| [177Lu]DOTATATENCT04609592 · Gastroenteropancreatic NETs | Phase 1 | Active, not recruiting | Stanford University | 1 |
| [177Lu]DOTATATENCT05249114 · NETs and neuroendocrine carcinomas (other) | Phase 1 | Active, not recruiting | Providence Health & Services | 1 |
| [177Lu]DOTATATENCT06632873 · Solid tumors (multiple indications) | Phase 1 | Recruiting | Peking Union Medical College Hospital | 1 |
| Trial | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
| [68Ga]Ga-DOTA-TATE/TOC/NOCNCT07119242 · NETs and neuroendocrine carcinomas (other) | Phase 3 | Active, not recruiting | HTA Co., Ltd. | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOC2024-519505-35-00 · Gastroenteropancreatic NETs | Phase 3 | Recruiting | Centre Hospitalier Universitaire De Nantes | 1 |
| DOTABREAST · [68Ga]Ga-DOTA-TATE/TOC/NOCNCT06611891 · Breast | Phase 3 | Recruiting | University Hospital, Grenoble | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOCNCT04888481 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Recruiting | University of Alberta | 1 |
| Antagoniste SSTR (LM3)NCT06455358 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Recruiting | University Hospital, Basel, Switzerland | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOCNCT02019706 · Adrenal | Phase 2 | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOCNCT07284589 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Recruiting | Akiva Mintz | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOC2024-516156-18-00 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Recruiting | Rigshospitalet | 1 |
| [18F]SSTR (SiTATE, AlF-NOTA-octreotide)2024-515636-77-00 · Atherosclerosis and vessels | Phase 2 | Recruiting | UZ Leuven | 1 |
| [18F]SSTR (SiTATE, AlF-NOTA-octreotide)NCT07104487 · Stroke and trauma | Phase 2 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOCNCT04559217 · Neuroblastoma | Phase 2 | Recruiting | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOCNCT07835906 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOC2023-504458-36-02 · Breast | Phase 2 | Recruiting | Centre Hospitalier Universitaire Grenoble Alpes | 1 |
| THERANOVA · [68Ga]Ga-DOTA-TATE/TOC/NOCNCT07178938 · Breast | Phase 2 | Not yet recruiting | MedSIR | 0 |
| NACASOR · [68Ga]Ga-DOTA-TATE/TOC/NOCNCT06982300 · Head and neck | Phase 2 | Recruiting | University Medical Center Groningen | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOCNCT05069220 · Neuroblastoma | Phase 1 | Recruiting | Peking Union Medical College Hospital | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOCNCT04040088 · Neuroblastoma | Phase 1 | Active, not recruiting | Mayo Clinic | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOCNCT05111509 · NETs and neuroendocrine carcinomas (other) | Phase 1 | Active, not recruiting | Yusuf Menda | 1 |
| DOTA-STR-17126 · Antagoniste SSTR (LM3)NCT07608848 · Prostate – other | Phase 1 | Recruiting | Integrated Haematology and Oncology Network | 1 |
| Antagoniste SSTR (LM3)NCT07288931 · Pheochromocytoma / paraganglioma | No phase | Recruiting | Peking Union Medical College Hospital | 1 |
| DOMINO-START · [68Ga]Ga-DOTA-TATE/TOC/NOCNCT04081701 · Neuroblastoma | No phase | Recruiting | Weill Medical College of Cornell University | 1 |
| OPERANDI-NET · [68Ga]Ga-DOTA-TATE/TOC/NOCNCT06256705 · Gastroenteropancreatic NETs | No phase | Recruiting | Assistance Publique - Hôpitaux de Paris | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOCNCT07366710 · Other | No phase | Active, not recruiting | Copenhagen University Hospital, Rigshospitalet | 1 |
| GATEDOTA · [68Ga]Ga-DOTA-TATE/TOC/NOCNCT06467968 · Inflammatory diseases | No phase | Recruiting | Central Hospital, Nancy, France | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOCNCT06500065 · Sarcoma / bone | No phase | Recruiting | Ohio State University Comprehensive Cancer Center | 1 |
| DOTA-LYME · [68Ga]Ga-DOTA-TATE/TOC/NOCNCT06392815 · Other | No phase | Recruiting | Copenhagen University Hospital, Rigshospitalet | 1 |
| Antagoniste SSTR (LM3)NCT07366099 · Solid tumors (multiple indications) | No phase | Recruiting | Peking Union Medical College Hospital | 1 |
| Antagoniste SSTR (LM3)NCT05873777 · Other | No phase | Recruiting | The First Affiliated Hospital of Xiamen University | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOCNCT06773624 · Gastroenteropancreatic NETs | No phase | Recruiting | European Institute of Oncology | 1 |
SSTR 2/3. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/sstr-2-3/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.